Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 130-134

  Hu, Xinhua ^a   Miao, Wei ^b   Zou, Yuanjie ^a   Zhang, Wenbin ^a   Zhang, Yansong ^a   Liu, Hongyi ^a  

^a THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Glioma; Ki 67; O O6 methylguanine DNA methyltransferase; P53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; EPENDYMOMA; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; PROTEIN EXPRESSION; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SUBEPENDYMOMA;

EID: 84878288004     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1317     Document Type: Article

References (27)

1. Kogiku M, Ohsawa I, Matsumoto K, et al: Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci 15: 1198-1203, 2008.
2. van den Bent MJ and Kros JM: Predictive and prognostic markers in neuro-oncology. J Neuropathol Exp Neurol 66: 1074-1081, 2007.
3. Noble M and Dietrich J: The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. Trends Neurosci 27: 148-154, 2004.
4. Kyritsis AP, Bondy ML, Hess KR, et al: Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1: 1617-1622, 1995.
5. Levidou G, El-Habr E, Saetta AA, et al: P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neurooncol 100: 363-371, 2010.
6. Hoelzinger DB, Mariani L, Weis J, et al: Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7: 7-16, 2005.
7. Shinojima N, Tada K, Shiraishi S, et al: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962-6970, 2003.
8. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al: Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 34: 674-679, 1994.
9. von Deimling A, Korshunov A and Hartmann C: The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21: 74-87, 2011.
10. 6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev 14: 1774-1783, 2005.
11. Fan KJ and Pezeshkpour GH: Ethnic distribution of primary central nervous system tumors in Washington, DC, 1971 to 1985. J Natl Med Assoc 84: 858-863, 1992.
12. Srivastava P, Jaiswal PK, Singh V and Mittal RD: Role of p53 gene polymorphism and bladder cancer predisposition in northern India. Cancer Biomark 8: 21-28, 2010-2011.
13. Pardo FS, Hsu DW, Zeheb R, Efird JT, Okunieff PG and Malkin DM: Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer 91: 1678-1686, 2004.
14. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
15. Bourdon JC, Laurenzi VD, Melino G and Lane D: p53: 25 years of research and more questions to answer. Cell Death Differ 10: 397-399, 2003.
16. Nicholas MK, Lukas RV, Jafri NF, Faoro L and Salgia R: Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12: 7261-7270, 2006.
17. De Luca A, Carotenuto A, Rachiglio A, et al: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567, 2008.
18. Wang A, Li J and Huang Q: Preliminary studies on the target inhibition effect of epidermal growth factor receptor inhibitor on proliferation of glioma cells. J Int Neurol Neurosurg 36: 189-192, 2009 (In Chinese).
19. Hofer S and Lassman AB: Molecular markers in gliomas: impact for the clinician. Target Oncol 5: 201-210, 2010.
20. Ambroise MM, Khosla C, Ghosh M, Mallikarjuna VS and Annapurneswari S: The role of immunohistochemistry in predicting behavior of astrocytic tumors. Asian Pac J Cancer Prev 11: 1079-1084, 2010.
21. Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
22. Gerdes J, Li L, Schlueter C, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873, 1991.
23. Johannessen AL and Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12: 143-147, 2006.
24. Habberstad AH, Gulati S and Torp SH: Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study. Diagn Pathol 6: 43, 2011.
25. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
26. 6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol 68: 603-609, 2007.
27. Yang Z, Deng Y, Fang J, et al: Expressions of LRP, MGMT and Topo & IIα in brain glioma and normal brain tissue and their significances. J Clin Res 25: 393-396, 2008 (In Chinese).